Latest News
Strategic Alliance aimed at business growth
14/07/10
A new strategic alliance between two Cambridge based companies will provide a comprehensive recruitment solution to the healthcare marketplace.
Angel Biotechnology - Appointment of Group Financial Controller and Company Secretary
07/07/10
Angel Biotechnology Holdings Plc, (AIM: ABH) the biopharmaceutical contract manufacturer, is pleased to announce the appointment of Lorna Peers FCCA as Group Financial Controller and Company Secretary.
Expansion at PiR Interims
06/07/10
Due to a significant increase in the demand for highly experienced interim professionals, PiR Interims, the leading provider of interim talent to the life science sector, is set for growth.
Dr Huw Jones appointed CEO, Atlantic Pharmaceuticals to lead growth of Atlantic Healthcare’s therapeutics division
02/07/10
Atlantic Healthcare Limited, an international specialist-led healthcare company, announces that Dr Huw Jones has been appointed Chief Executive of Atlantic Healthcare’s therapeutics division, Atlantic Pharmaceuticals Limited and joins the board of Atlantic Healthcare.
Synairgen plc - Directorate appointment
30/06/10
Southampton, UK – 28 June 2010: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company with a particular focus on viral defence in asthma, COPD and flu, is pleased to announce the appointment of Iain Peter Murray Buchanan to the Board.
Retroscreen appoints Jody Cheng as Vice President, Translational Research
30/06/10
Retroscreen Virology Limited, a global leader in anti-viral research, clinical trials and experimental challenge studies, is pleased to announce that Dr Jody KN Cheng has been appointed Vice President, Translational Research with immediate effect. Jody will assume overall responsibility for Retroscreen’s analytical and laboratory capabilities
Simon Saxby Joins Board at Selcia
30/06/10
Ongar, Essex, United Kingdom (28 June 2010). Selcia Limited, a leading provider of contract research services in 14-C custom radiolabelling, integrated drug discovery, fragment screening and medicinal chemistry today announced the high profile appointment of Simon Saxby to the Board as a non-executive director.
Aquapharm appoints new Chief Scientific Officer
30/06/10
Aquapharm Biodiscovery, a leading marine biotechnology company, announced today the appointment of Dr Tim Morley as Chief Scientific Officer (CSO). Dr Morley’s appointment follows an investment of £4.2 million from existing investors and the appointments of biotech entrepreneur Simon Best as CEO and Aquapharm’s founder Dr Andrew Mearns-Spragg as CTO in March 2010.
ReGen Therapeutics to raise £100,000
30/06/10
ReGen Therapeutics Plc ("ReGen" or the "Company"), (AIM:RGT) is pleased to announce that it has conditionally placed 5,000,000 new ordinary shares at 2p per ordinary share to raise £100,000 before expenses for general working capital purposes.
Aesica acquires R&D company R5
30/06/10
Aesica Pharmaceuticals has acquired R&D company R5, which develops and manufactures new medicines and clinical trial materials.
Biogen Idec Names George Scangos Chief Executive Officer
30/06/10
Biogen Idec (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced that George A. Scangos, Ph.D., has been appointed Chief Executive Officer (CEO), effective July 15. Dr. Scangos will also be named to the Board of Directors.
SkyePharma PLC - Director Declaration - Update
25/06/10
SkyePharma appointed Dr. Thomas Werner as Chairman of its Remuneration Committee in place of Frank Condella. Frank Condella remains Chairman of the Company.
Tim Sharpington appointed CEO of Phytopharm
24/06/10
Phytopharm plc (LSE: PYM) ("Phytopharm" or the "Company") today announces the appointment of Mr Tim Sharpington as Chief Executive Officer and as a Board Director with effect from 06 July 2010.
Syntopix Group plc - Directorate Change
24/06/10
Syntopix Group plc (AIM:SYN), the speciality research and development company focused on the discovery of topical antimicrobials for healthcare and pharmaceutical applications, today announces the following Board change with immediate effect.
PolyTherics appoints new Chairman
21/06/10
PolyTherics, the biopharmaceutical company dedicated to precision engineering of proteins and peptides to improve their pharmacokinetic properties, announced that Dr Ken Cunningham has been appointed Chairman.
Back to Top